Mixed trend on the daily chart: below its 50-day average · SuperTrend down since Sep 23 · RSI 28 (oversold) · MACD below its signal · 6% above its 52-week low
| 28.00 | Previous month high | +103.93% |
| 28.00 | 52-week high | +103.93% |
| 17.80 | R3 (classic) | +29.64% |
| 16.67 | R2 (classic) | +21.41% |
| 16.62 | Previous month low | +21.05% |
| 16.30 | Previous week high | +18.72% |
| 15.54 | Previous day high | +13.18% |
| 15.20 | R1 (classic) | +10.71% |
| 14.07 | Pivot | +2.48% |
| 13.73 | Price now | |
| 12.94 | Previous day low | −5.75% |
| 12.94 | Previous week low | −5.75% |
| 12.94 | 52-week low | −5.75% |
| 12.60 | S1 (classic) | −8.23% |
| 11.47 | S2 (classic) | −16.46% |
| 10.00 | S3 (classic) | −27.17% |
No member of Congress has disclosed a ATTO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
None of the 29 investors followed here reported a position in ATTO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 5, 2026 | Sanofi SaBeneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | 300K | $5.10M |
| Aug 5, 2026 | Sanofi SaBeneficial Owner of more than 10% of a Class of Security | — | 782.9K | — |
| Aug 5, 2026 | Redmile Group, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | 600K | $10.20M |
| Aug 5, 2026 | Redmile Group, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 782.9K | — |
| Aug 5, 2026 | Goldman Sachs Group Inc.Unknown | Purchase at price 17.00 - 21.00 per share. | 585K | $10.29M |
| Aug 5, 2026 | Goldman Sachs Group Inc.Unknown | — | 2.44M | — |
| Aug 5, 2026 | Goldman Sachs Group, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 - 21.00 per share. | 585K | $10.29M |
| Aug 5, 2026 | Goldman Sachs Group, Inc.Beneficial Owner of more than 10% of a Class of Security | — | 2.44M | — |
| Aug 5, 2026 | Walsh ColinDirector | Purchase at price 17.00 - 21.00 per share. | 585K | $10.29M |
| Aug 5, 2026 | Walsh ColinDirector | — | 2.44M | — |
| Aug 5, 2026 | Walsh ColinDirector | Purchase at price 17.00 - 21.00 per share. | 585K | $10.29M |
| Aug 5, 2026 | Walsh ColinDirector | — | 2.44M | — |
| Aug 5, 2026 | Frazier Life Sciences X, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | 588.2K | $10.00M |
| Aug 5, 2026 | Frazier Life Sciences X, L.P.Beneficial Owner of more than 10% of a Class of Security | — | 5.49M | — |
| Aug 5, 2026 | Deep Track Biotechnology Master Fund LtdBeneficial Owner of more than 10% of a Class of Security | — | 1.96M | — |
| Aug 5, 2026 | Frazier Life Sciences Xi , L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | 588.2K | $10.00M |
| Aug 5, 2026 | Frazier Life Sciences Xi , L.P.Beneficial Owner of more than 10% of a Class of Security | — | 5.49M | — |
| Aug 5, 2026 | Venbio Global Strategic Fund Iv, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | 382.4K | $6.50M |
| Aug 5, 2026 | Venbio Global Strategic Fund Iv, L.P.Beneficial Owner of more than 10% of a Class of Security | — | 3.80M | — |
| Aug 4, 2026 | Goldman Sachs Group Inc.Unknown | Sale at price 20.84 - 22.19 per share. | 105.8K | $2.25M |
TimeframesDown on all 2 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Buy / hold / sell counts